Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$6.51M Sell
261,420
-27,740
-10% -$700K 0.38% 58
2025
Q3
$7.37M Sell
289,160
-643
-0.2% -$15.9K 0.45% 50
2025
Q2
$7.02M Buy
289,803
+30,632
+12% +$714K 0.46% 50
2025
Q1
$6.57M Buy
259,171
+290
+0.1% +$7.59K 0.47% 49
2024
Q4
$6.87M Sell
258,881
-70,812
-21% -$1.92M 0.47% 44
2024
Q3
$9.54M Buy
329,693
+54,490
+20% +$1.59M 0.66% 34
2024
Q2
$7.7M Buy
275,203
+5,079
+2% +$140K 0.58% 37
2024
Q1
$7.5M Sell
270,124
-18,891
-7% -$524K 0.55% 42
2023
Q4
$8.32M Buy
289,015
+203,084
+236% +$6.14M 0.68% 35
2023
Q3
$2.85M Sell
85,931
-6,792
-7% -$240K 0.25% 81
2023
Q2
$3.4M Sell
92,723
-2,490
-3% -$96.9K 0.3% 73
2023
Q1
$3.88M Buy
95,213
+2,583
+3% +$112K 0.36% 67
2022
Q4
$4.75M Sell
92,630
-558
-0.6% -$26.8K 0.44% 54
2022
Q3
$4.08M Buy
93,188
+75,415
+424% +$3.66M 0.42% 60
2022
Q2
$932K Sell
17,773
-933
-5% -$47.5K 0.13% 85
2022
Q1
$968K Sell
18,706
-830
-4% -$43.1K 0.12% 93
2021
Q4
$1.15M Sell
19,536
-2,210
-10% -$109K 0.14% 88
2021
Q3
$935K Sell
21,746
-1,030
-5% -$45.6K 0.13% 94
2021
Q2
$892K Buy
22,776
+330
+1% +$12.8K 0.13% 96
2021
Q1
$813K Sell
22,446
-153,514
-87% -$5.45M 0.12% 104
2020
Q4
$6.48M Buy
175,960
+9,133
+5% +$335K 1.02% 26
2020
Q3
$5.81M Sell
166,827
-4,149
-2% -$145K 1.14% 21
2020
Q2
$5.3M Buy
170,976
+1,834
+1% +$62.3K 1.09% 23
2020
Q1
$5.24M Buy
169,142
+38,021
+29% +$1.3M 1.32% 18
2019
Q4
$4.87M Buy
131,121
+11,449
+10% +$408K 0.9% 27
2019
Q3
$4.08M Buy
119,672
+6,448
+6% +$234K 0.38% 47
2019
Q2
$4.65M Buy
113,224
+7,300
+7% +$290K 0.45% 38
2019
Q1
$4.27M Buy
105,924
+2,230
+2% +$89.3K 0.43% 36
2018
Q4
$4.29M Buy
103,694
+8,797
+9% +$365K 0.51% 28
2018
Q3
$3.97M Buy
94,897
+1,734
+2% +$66.8K 0.37% 36
2018
Q2
$3.21M Buy
93,163
+1,627
+2% +$55.6K 0.29% 51
2018
Q1
$3.08M Buy
91,536
+2,321
+3% +$79.8K 0.3% 51
2017
Q4
$3.07M Buy
+89,215
New +$3.04M 0.29% 48

Other funds holding PFE

Cadence Bank's PFE Position: Q4 2025 in Review

Cadence Bank reduced its Pfizer (PFE) stake by 9.6% in Q4 2025, selling an estimated $700K and leaving 261,420 shares worth $6.51M. The position accounts for 0.38% of the portfolio, ranked #58.

Cadence Bank first reported a position in PFE in Q4 2017 and has held it in 33 quarters since. The position peaked at $9.54M in Q3 2024. 2,905 funds tracked by Wall St. Rank hold PFE as of Q4 2025.

  • Cadence Bank held 261,420 shares of Pfizer worth $6.51M as of Q4 2025.
  • Cadence Bank sold 27,740 Pfizer shares in Q4 2025, an estimated $700K.
  • Pfizer made up 0.38% of Cadence Bank's portfolio in Q4 2025, its #58 holding.
  • Cadence Bank first reported a position in Pfizer in Q4 2017 and has held it in 33 quarters since.
  • Cadence Bank's Pfizer position peaked at $9.54M in Q3 2024.
  • 2,905 funds tracked by Wall St. Rank held Pfizer as of Q4 2025.

Based on Cadence Bank's 13F filing for Q4 2025, filed 30 Jan 2026.